|Day Low/High||0.43 / 0.46|
|52 Wk Low/High||0.61 / 1.78|
Shipment Size for Fourth Quarter of 2017 Represents Annual Revenues of approximately $42 Million
Approval further supports the advanced ongoing discussions with the Brazilian Ministry of Health for the supply of a significant amount of alfataliglicerase for Gaucher patients in Brazil
Six Sites Activated Across the United States and Europe with additional patients currently in the screening process for potential inclusion in trial
These stocks trading for less than $10 a share are within range of triggering big breakout trades.
Insiders at these companies have been scooping up shares of their own stock lately.
Positive Pre-Clinical Data for PRX-106 Oral Anti-TNF in NASH